Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

PURPOSE: Based on promising predinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2(mut) nonamplified metastatic breast cancer (MBC). Secondary endpoints i...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Ma, Cynthia X., Bose, Ron, Gao, Feng, Freedman, Rachel A., Telli, Melinda L., Kimmick, Gretchen, Winer, Eric, Naughton, Michael, Goetz, Matthew P., Russell, Christy, Tripathy, Debu, Cobleigh, Melody, Forero, Andres, Pluard, Timothy J., Anders, Carey, Niravath, Polly Ann, Thomas, Shana, Anderson, Jill, Bumb, Caroline, Banks, Kimberly C., Lanman, Richard B., Bryce, Richard, Lalani, Alshad S., Pfeifer, John, Hayes, Daniel F., Pegram, Mark, Blackwell, Kimberly, Bedard, Philippe L., Al-Kateb, Hussam, Ellis, Matthew J.C.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6746403/
https://ncbi.nlm.nih.gov/pubmed/28679771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0900
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki